Discospondylitis describes the infection of an intervertebral disc and its adjacent cartilaginous end plates and vertebral bodies.
It is commonly bacterial or fungal in origin.
The disease can be challenging to diagnose as signs are variable and sometimes vague.
For the research, neurology specialists retrospectively examined cases which presented at multiple referral sites that have furthered the understanding, clinical and imaging features of discospondylitis.
To date MRI has been the imaging modality of choice, with consistent CT imaging features of discospondylitis in dogs and cats not previously reported in detail.
However with the increased availability of CT in clinical practice, the research set out to examine CT features that could support a diagnosis of discospondylitis.
Discospondylitis in cats is uncommon, and very little research had been undertaken in this area. This research group therefore reported clinical presentation and imaging data about a population of cats, to support the future diagnosis of these cases.
During the three studies*, the researchers found that:
The studies
The RCVS announced in a tweet yesterday afternoon that it will be retaining postnominals on the Register.
#RCVScouncil agrees to retain postnominals on Register. Proposals to improve clarity to come back to future meeting. — RCVS (@RCVS_UK) June 5, 2014
#RCVScouncil agrees to retain postnominals on Register. Proposals to improve clarity to come back to future meeting.
VetSurgeon understands that the proposals to improve clarity may yet involve some rationalisation of the postnominals that will be displayed, but that RCVS Certs and Diplomas will remain.
The decision represents something of a victory for Victoria Lilley’s campaign and yet another indication that under the stewardship of Nick Stace, the RCVS really is evolving to become a more open, responsive organisation.
The guide has been written by Simon Tappin, European and RCVS Recognised Specialist in Veterinary Internal Medicine at Dick White Referrals, and is designed to offer practical advice on the appropriate use of antibiotics in general practice. It covers a range of topics including how to create an antibiotic practice policy, ways to optimise therapy and how to limit the development of antimicrobial resistance.
Simon said: "Making rational and informed antimicrobial choices is vitally important in veterinary medicine, both for the welfare of our patients and in reducing the risk of developing antimicrobial resistance.
"Highlighting this issue to vets, providing education and supporting them in making these decisions is crucial to ensure a responsible approach to antimicrobial prescribing."
Recent surveys have highlighted the need for education on this topic, with 63 per cent of vets1 stating that they would like to improve their knowledge on antimicrobials, and 90 per cent of vets2 admitting that they are concerned about antimicrobial resistance.
In addition, there's a quiz where you can test and your knowledge on antimicrobials, and enter a competition to win an iPad Pro. The quiz can be accessed at https://veraflox.typeform.com/to/KY8lxX.
The guide is available from the Bayer Vet Centre, www.vetcentre.bayer.co.uk. Alternatively, you can download it here www.bit.ly/Veraflox2016 or contact your local Bayer Territory Manager.
References
Matthew’s award is in recognition of his paper Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom, co-authored with Laurent Garosi, which was selected by the BSAVA Committee as being the most valuable to veterinary practice.
James’ study explored data collected as part of the Small Animal Veterinary Surveillance Network (SAVSNET) at the University of Liverpool.
In total, clinical records concerning 3,150,713 consultations (917,373 dogs) were collected and analysed from 224 UK veterinary practices.
This included the management of canine generalised epileptic seizures in 517 dogs up to 6 years of age.
The study concluded that 98% of dogs presenting for a single epileptic seizure were not started on long-term therapy, in accordance with the approach recommended by the International Veterinary Epilepsy Task Force (IVETF).
Other findings from the study included:
The paper also reported on factors potentially associated with prescription of ASDs.
It stated that dogs who presented for cluster seizures (more than one epileptic seizure in a 24-hour period) were more likely to be prescribed ASDs, or to be referred to a specialist, than dogs without cluster seizures.
Dogs that were neutered or microchipped were more likely to be started on ASDs following the initial presentation, perhaps suggesting that owners who take part in regular preventative healthcare prior to the onset of their dog’s seizures could be more willing to start therapy in the earlier stages of the disease.
In addition, more than half of dogs with cluster seizures were not prescribed any ASDs.
Given that the presence of cluster seizures is typically considered an indication to start long-term therapy by the IVETF, Matthew says this may be one aspect of seizure management that could be improved in primary care practice.
Regarding the choice of anti-seizure drugs (ASDs), imepitoin was more frequently prescribed than phenobarbital in response to cluster seizures.
But unlike phenobarbital, the paper highlighted that the market authorisation for imepitoin does not include the treatment of cluster seizures.
Therefore vets should be aware that the use of imepitoin for cluster seizures should be considered as “off-licence” - and has additional implications for obtaining informed consent.
Matthew said: “We believe this research contributes to an improved understanding of the current management strategies for canine epilepsy in general practice and how this compares to the current guidelines advised by the IVETF.
"Given the prevalence of epileptic seizures within the UK canine population, as well as the large proportion of dogs that will be managed entirely within general practice without referral to a neurologist, it is vital to ensure that the level of care being provided is optimal.
"We therefore hope that this research ultimately supports and guides general practitioners in their approach to canine epilepsy, thereby improving the quality of life of affected dogs and their owners.”
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13543
Dr Kalisz faced a total of nine charges (including 41 sub-charges).
The first was that in July 2020, she failed to carry out a clinical examination of the dog, failed to adequately interpret test results, failed to ask for help interpreting the results, and undertook an emergency Caesarean section without sufficient need to do so.
The other charges related to undertaking a colotomy without sufficient justification and without exercising sufficient clinical judgment throughout the procedure.
For both the Caesarean section and the colotomy, Dr Kalisz faced charges that she failed to obtain informed consent from the owners and failed to inform them that the colotomy had been carried out, or of the potential risks of the procedure, and also failed to provide enough information about aftercare.
It was also alleged that Dr Kalisz had demonstrated continual lapses in professional judgement, including failing to appropriately manage the spaniel’s worsening condition when it was presented to the practice again later, and that the clinical records in relation to the surgery were dishonest and/or misleading.
Dr Kalisz admitted serious professional misconduct, admitting to 29 of the sub-charges, while the remaining 12 sub-charges were denied.
The Committee found 30 of the sub-charges proven, with the remaining 11 not proven.
The Committee the considered aggravating factors, including the fact that Dr Kalisz's conduct led to the spaniel’s death, the colotomy was reckless and Dr Kalisz did not take steps to inform anybody or make a clinical record for the colotomy.
In mitigation, the Committee considered the fact that it was single and isolated incident (albeit one that spanned a number of days), that no other members of the clinical team involved raised concerns during the procedure, and the effect Covid had upon the veterinary profession.
The Committee found that of those charges proven, the ones relating to performing the colotomy, failing to manage the spaniel’s subsequent care and failing to mention the colotomy amounted to serious professional misconduct.
On deciding the sanction, the Committee took into account the mitigation submitted on behalf of Dr Kalisz and the written testimonials produced including the fact that she was young and inexperienced, had admitted her failings at an early stage, had made subsequent efforts to avoid a repetition of such behaviour and that a significant amount of time had passed since the incident.
The Committee also considered that Dr Kalisz had shown an exemplary level of insight, showing remorse for her actions, undertaking substantial continuing professional development, and finding appropriate ongoing professional mentorship.
The Committee was impressed by the character testimonials from veterinary co-workers, both current and at the time of these events, as well as from clients.
It was, the Committee said, apparent from those testimonials that Dr Kalisz had been open and honest with them about the charges and was considered to be an excellent, committed veterinary surgeon.
Paul Morris, chairing the Committee and speaking on its behalf said: “The Committee found that this was a single isolated incident, which involved serious lapses of clinical judgement.
"It was therefore concluded that, despite Dr Kalisz’s actions being reckless, the extensive mitigation and the high level of insight, coupled with steps taken to avoid repetition, meant that there was negligible future risk to animal welfare.
“The Committee did not consider it necessary to issue a warning to Dr Kalisz about her future conduct, on the basis that the Committee has concluded that there is little risk of repetition, so considered that a reprimand would be an appropriate sanction in this case.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Ceva Animal Health has launched a new broad-spectrum, flavoured endoparasiticide tablet, Milbactor for dogs.
Milbactor contains milbemycin oxime and praziquantel, which offer protection against the common nematodes seen in the UK and the main species of tapeworm.
Milbemycin oxime treats Toxocara canis and Toxascaris leonina, Angiostrongylus vasorum and Crenosoma vulpis, the hookworm Ancylostoma caninum, the whipworm Trichuris vulpis and the eyeworm, Thelazia callipaeda. Milbactor also prevents heartworm disease caused by Dirofilaria immitis.
Praziquantel protects against Echinococcus spp., Dipylidium caninum, Taenia spp. and Mesocestoides spp.
Puppies weighing more than 0.5 kg can be treated with Milbactor from two weeks of age. Milbactor comes in two tablet sizes for dogs and puppies, and the tablets are flavoured for easy administration.
Ceva has also launched The Ceva Protection System for dogs, a two-step solution featuring Vectra 3D and Milbactor to provide ectoparasite and endoparasite protection for dogs with one monthly topical treatment and one flavoured tablet. The Ceva Protection System uses Vectra Felis for flea protection for cats and Acclaim for the treatment of the pet's home environment.
Rob McLintock MRCVS, companion animal business unit manager at Ceva Animal Health, said: "The launch of Milbactor and The Ceva Protection System will enable veterinary surgeons to offer their clients a simple regime featuring Vectra 3D and Milbactor for comprehensive parasite control in dogs. Offering protection both inside and out and with no bite required to kill fleas, the regime offers a simple, effective combination to treat and prevent fleas, ticks, biting flies, roundworms, tapeworms, lungworms and to prevent heartworm.
For further information on The Ceva Protection System, Milbactor, Vectra 3D or Vectra Felis, contact your local Ceva territory manager or call 01494 781510.
The company says the acquisition is a natural fit for its behavioural range and will bolster its Adaptil portfolio with a wider variety of anxiety solutions for dogs.
Abbie King, senior behaviour product manager at Ceva Animal Health, said: “We have always been fans of the ThunderShirt range and we are therefore delighted with the acquisition, which will further strengthen our extensive portfolio of behavioural products that work in synergy with one another to provide pet owners with comprehensive anxiety solutions.”
For more information, visit: www.thundershirt.com
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
John Innes, CVS Referrals Director based at Chester Gates Veterinary Specialists (BVSc PhD CertVR DSAS (orth) FRCVS), said: "The main challenges around managing and treating osteoarthritis for vets is that it is a chronic, insidious problem.
"It’s also often lower down the priority list and owners don’t recognise the signs; they often ascribe it to ageing. Actually, osteoarthritis is such a common problem that it should be way up our priority list because something like 10-15% of adult dogs have OA."
The roundtable discussion also focused on the need for greater understanding of the condition among pet owners.
Duncan Lascelles, Professor of Small Animal Surgery and Pain Management at NC State Veterinary Medicine (BSc, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DECVS, DACVS) said: "The vet profession needs to take a much more active role in the education of owners, and osteoarthritis is a perfect example of this. Many owners consider osteoarthritis to be age related and an inevitable part of the ageing process – unfortunately both of those concepts are erroneous.
"Osteoarthritis can be a young dog disease, it is present in many young dogs because it is caused by developmental diseases, but we only recognise the obvious signs later on when the disability is severe. Also, we should not consider OA-related pain as an inevitable part of the ageing process, it is something that we can prevent by early intervention, early treatment and modification of lifestyle."
Meanwhile, a survey of 236 UK practising vets carried out by Elanco last June, revealed that 76% of veterinary surgeons believe owners fundamentally misunderstand OA and consider it just a symptom of old age, which results in a barrier to effective treatment of the disease.
The survey also found that although the illness is commonplace (49% of veterinary surgeons see OA cases every day), vets are often unable to give their preferred treatment for OA for a range of reasons, from owner misconception of the disease through to perceived side effects and compliance.
The issue of better education of owners was also discussed at the roundtable, in particular the role of CMIs (Clinical Metrology Instruments); owner-facing questionnaires designed to help veterinary surgeons evaluate the extent and seriousness of OA-related pain in dogs.
Duncan said: "The great thing about CMIs is that they have been constructed using language that owners understand, therefore are an easy way to ask owners the right questions in the way that they will understand.
"CMIs allow us to have what can be very difficult conversations with owners. Difficult because we have to think of all the different ways that osteoarthritis might be affecting pets. Because the CMIs include pre-constructed questions, it means that conversations with owners are much easier and, importantly, they’re consistent. Consistency is key to ensure you’re asking the same set of questions each time, every time, so you can follow the evolution of clinical signs over time and assess the beneficial impact of our therapeutics."
John added: "We often quiz the owner informally in a consultation, but CMIs gives us the tools needed to formalise this questioning of clients and allow us to put that in context of our knowledge of other patients."
Both John and Duncan said the need for more patient analysis highlighted the need for better use of existing tools, such as the LOAD (‘Liverpool Osteoarthritis in Dogs’) questionnaire, a 13-item clinical metrology instrument (CMI) designed to help veterinary surgeons determine the severity of OA in all dogs, monitor disease progression and assess the patient’s response to treatment.
For more information contact your Elanco representative or call +44 (0)1256 353131.
Centaur has launched a new service on the MyCentaur website which allows for 24-hour ordering from any broadband enabled computer.
A secure practice shopping list with controlled staff access to ordering and management information enables practices to safely control any buying.
According to the company, a key feature of the website is that any orders placed on line by 9pm will be delivered the following day, which gives practices even greater flexibility on ordering times over any existing vet wholesaling ordering service. As well as greater convenience, a financial benefit in using this method of ordering is that all on-line orders attract an additional two per cent discount.
Jonathan Hill (UK Country Manager) said: “I’m delighted to announce that TVM UK is changing its name to Dômes Pharma.
"This will align with the other operating companies within the group.
"TVM UK has always been owned by the Dômes Pharma group, and since the start of our journey in the UK market we have been synonymous with expertise and outstanding levels of customer service in selected speciality segments of the animal health market and this won’t change.”
“Under the Dômes Pharma name we will continue to build and grow on this very strong foundation.
"I’m looking forward to working with the entire Dômes Pharma team as we increase our presence as a leading specialty pharmaceutical company, bringing our ethos to new speciality segments with innovative products and solutions for vets in the UK.
"Dômes Pharma remains a family-owned business, and the culture of the company really reflects this and we live by our values of kindness, boldness and responsibility.” https://www.domespharma.com https://www.tvm-uk.com
The programme includes a mix of online and in-person sessions hosted by Blaise's multi-disciplinary team.
Lara Dempsey, head of soft tissue surgery at the hospital, will start with ‘To close or not to close, that is the question’ on Monday 27th January.
Lara's online session will cover tips and tricks for open wound management and wound closure options, case studies and her preferred products to use in practice.
On Thursday 8th May, head of anaesthesia and analgesia Jacques Ferreira (pictured) will host a one-day workshop on pain management, taking place at Blaise.
Attendees will develop their understanding of acute and chronic pain, and the difference between them.
Jacques will also discuss the future of nerve blocks and share techniques that can be used in practice.
Julie Davis, hospital director at Blaise, said: “We have an incredible team here at Blaise and are very much looking forward to sharing our collective knowledge with colleagues from across the veterinary profession.
The full programme of free CPD events:
www.blaise-referrals.com/vet-hub/cpd-events
A campaign to reform English libel law to allow for robust criticism of scientific and medical claims without fear of legal action has been launched by journalist and author Simon Singh. It's a campaign which anyone working in the caring professions might wish to support.
The campaign comes as a consequence of legal action taken against Mr Singh by The British Chiropractic Association, which took exception (perhaps unsurprisingly) to an article he'd written in The Guardian. In the article, Mr Singh denounced claims on the BCA website that its members could use spinal manipulation to treat children with colic, ear infections, asthma, sleeping and feeding conditions, and prolongued crying as 'bogus', and criticised the BCA for 'happily promoting' these claims.
Out of curiosity, VetSurgeon rang the BCA press office this morning, and asked to be given the references for studies which it feels would support the original claims made on its site. Non have been forthcoming so far, which is a surprise. Under the circumstances, we'd have expected the BCA would have a raft of supporting evidence readily available.
But this isn't really about whether or not chiropractic works or not. The case seems to hinge upon whether Mr Singh's article implied that the BCA was being deliberately dishonest, or just delusional. He say's the latter. Unfortunately for him, Mr Justice Eady recently ruled the former, leaving Mr Singh with a bill for £100,000 worth of legal fees.
Mr Singh is to appeal. At stake is the freedom to be able to challenge scientific claims without fear of being sued. If you'd like to support this campaign, visit senseaboutscience.com and add your name to the 7000 others (including some pretty illustrious names) who have already done so.
Animalcare's new Cephacare flavour antibiotic has received a response of 'good' or 'very good' in 80% of cases in a recent field study of superficial pyoderma in dogs. When asked to rate the effectiveness of the cephalexin-based antibiotic, more than half of the cases were awarded the highest response level of 'very good'.
Animalcare asked vets from across the country to participate in the study in order to confirm the company's own opinion. Each vet recorded five cases of superficial pyoderma in dogs and scored the effectiveness of treating the condition with Cephacare flavour. The first vets to complete their assessment forms received a free copy of the BSAVA Manual of Small Animal Dermatology worth £85.
The antibiotic proved effective across 19 different breeds, with animal weights ranging from 7kg to 70kg. Varying degrees of condition severity from mild through to severe were recorded with the average treatment length being 14-17 days. A number of 'severe' cases were treated with positive results. Severe was defined as long standing or recurrent areas of papules, crusting papules, epidermal collarettes and intact pustules.
Tony Liepman, Animalcare Market Manager, said: "A study like this confirms the product's effectiveness and, importantly, the acceptance of Cephacare flavour in real-world cases."
The protocol provides evidence-based best practice criteria so that hospitals and other health settings can introduce animals into the care environment.
By following it, the RCN says services will be able to ensure the safety of patients and health care staff as well as the animals and their owners, while allowing patients to reap the benefits that interaction with animals can bring.
Publication of the protocol was prompted by an RCN survey last year which found that although the majority of respondents thought animals were hugely beneficial to patients, most nurses said animals were not allowed in their workplace.
The survey found that nine out of 10 nurses believe animals can help improve the health of patients with depression and other mental health problems with 60% of respondents also acknowledging that animals can help speed patient recovery.
Amanda Cheesley, RCN Professional Lead for Long-term Conditions and End-of-Life Care, said: "Anyone who’s worked in this area can see the amazing impact animals have on the health of adults and children alike.
"However there are so many myths around the dangers of having animals in health care settings that most organisations are too concerned to try it out.
"This protocol will help to dispel these fears by supporting hospitals to include animals in the care they deliver in a safe and professional way.
"We hope that it will encourage all health services to consider how animals can help their patients and help us to remove the taboo from what is a really remarkable area of care."
The protocol has been welcomed by the British Veterinary Association. Simon Doherty, BVA Junior Vice President, said: "This new protocol highlights the importance of the bond between humans and animals. It also serves as a welcome reminder at the start of Mental Health Awareness Week of how caring for and interacting with ‘man’s best friend’ can help to relieve stress and enhance wellbeing and a sense of companionship.
"It’s positive that the working group consulted with a wide range of organisations on welfare and safety considerations in developing this protocol, as ensuring the wellbeing of both humans and animals in these settings is paramount. As a fellow member of the UK One Health Coordination Group, BVA is very pleased to see a joined-up and forward-thinking approach to this important area of work."
Photo: Therapy Dog Visiting Young Female Patient In Hospital, Monkey Business Images / Shutterstock
The new programme includes ten days of practical imaging sessions based at CPD Solutions' training centre in Studley near Birmingham, where participants will develop their existing imaging skills and learn additional techniques that they can use directly in small animal practice.
CPD Solutions says its PgCerts have unique benefits and key differences from other PgCert options available to vets, namely a strong emphasis on practical training (all attendance days are practical, with no lecture days), the way the attendance days are grouped into three sessions for convenience, and the 12 month duration of the programme.
Susie Coughlan, veterinary surgeon and MD at CPD Solutions has 21 years’ experience in providing practical training for vets. ‘Our experience is that vets get the most out of hands-on practical training in a structured and supportive environment, combined with reflective application of their new skills in practice. The new PgCert in Small Animal Diagnostic Imaging follows the same format – all attendance sessions are practical, and the course provides support for developing reflective work based learning that vets can use with all of their patients.’
For more information, contact CPD Solutions on 0151 328 0444 or visit www.pgcert.com
California-based Signostics, Inc. has launched SpeqViewTM, billed as the world's smallest and most cost-effective veterinary ultrasound device.
Using MotionScape and SectorView technology, and offering multiple transducer frequencies, the SpeqView delivers high-resolution images for key veterinary applications including: cystocentesis; bladder volume; foreign object localization; abdominal imaging; and musculo-skeletal diagnosis.
Jeff Green, Signostics Vice-President of Sales and Marketing said: "The SpeqView provides a break-through for veterinary practices. For the first time there is an ultrasound device that is highly portable, simple to use and individually affordable. The SpeqView improves veterinary practice efficiency and income by allowing immediate diagnosis in the consulting room, or in the field and by providing better animal care.
He added: "Weighing a little over half a pound, the SpeqView features extended battery life and amazing portability, and is worn around your neck like a stethoscope or placed in your pocket until the next use."
The SpeqView is configured to use 3.5MHz and 7.5MHz transducers and comes with a comprehensive warranty, which covers the system and transducers and eliminates the need for annual service contracts. Signostics also offers extensive training and education programs delivered on site, online and in collaboration with leading veterinary institutions and educators. No interest, twelve-month financing is available.
For more information visit www.SpeqView.com or contact Signostics on 001 877 5744667.
Merial Animal Health has launched Allevinix, a flunixin-based non-steroidal anti-inflammatory (NSAID) pain killer for cattle, pigs and horses.
Victoria Hudson, Product Manager for Merial Animal Health said: "We have positioned Allevinix as the flexible flunixin that meets your needs, because it offers flexibility in every area.
"It is the only flunixin licensed for both intramuscular and intravenous administration in cattle and we know that this will be very welcome for many vets and farmers. It can be used across cattle, pigs and horses, and it is the first injectable NSAID to come in a durable, non-breakable bottle."
Merial says Allevinix is fast-acting against inflammation, pain and fever, reaching peak plasma levels approximately 30 minutes after injection. It is available in 100ml and 250ml PET bottles and joins Ketofen as part of a range of NSAIDs available from Merial. It can also be used in conjunction with Merial's antimicrobial treatment for calf pneumonia - Zactran.
Victoria added: "We believe that vets will find this is a useful and innovative addition to the range of options that they have in terms of NSAIDs. Allevinix has a number of advantages over other flunixin products currently on the market."
The competition is open to all UK-based undergraduate veterinary students and offers them the opportunity to work as a team to brainstorm, develop and present an innovative idea to a board of industry professionals.
Students can enter either as a single applicant or as a group (of roughly five members), with single applicants then being placed in a group with other applicants from their university. There can be more than one team representing each university.
Each student’s project can cover any aspect of veterinary health innovation. The RCVS suggests potential projects might include: innovations within veterinary education, innovations to improve sanitation and hygiene, innovations to improve veterinary-public communication and innovations to improve patient safety.
Entries must show how they have improved upon – or extended beyond – current expectations of best practice in their chosen area.
Each applicant will receive support from one of the Association of Veterinary Students’ (AVS) Vet Futures Ambassadors, as well as a mentor session with a chosen industry professional to guide them on their project.
Teams will need to submit three components for judging: a log of their progress throughout the project (which can include social media updates using the hashtag #ViVetStudentInnovation), mentor engagement and feedback, and a five-minute video ‘business pitch’.
The three finalist groups of the competition will be invited to present their pitch to a board of industry professionals at a ‘Dragon’s Den’ style event held at the RCVS ViVet 2019 Innovation Symposium on Tuesday 1 October 2019 in Manchester.
The winning and runner-up groups will then be selected and will be presented alongside the ‘mentor’s choice’ award. The Mentor’s Choice award will be selected by the team mentors. The prize will be awarded to an individual who shows excellence and enthusiasm within their work on the project.
Anthony Roberts, RCVS Director of Leadership & Innovation (pictured right), said: "This competition provides a great opportunity for veterinary students to engage with their fellow classmates across different fields of study and to work on projects that could genuinely make a difference to animal health and welfare and the way veterinary services are delivered. Teams will receive one-on-one mentoring and will be guided through the innovation process, developing skills that will be useful throughout their careers. We look forward to seeing the three finalist teams presenting at the RCVS ViVet Innovation Symposium in Manchester on 1 October."
Zoe Skinner, Vet Futures Student Representatives Team Leader, said: “This competition is a great opportunity for veterinary students to receive mentoring from experienced veterinary professionals and form contacts within our profession. It gives students a way to work together as a team and allows them to learn how to produce and develop innovative, problem-solving concepts as well as skills in delivering presentations. These are all important aspects of our career ahead, which will look brilliant on our CV’s.”
ViVet is now accepting registrations for the competition for the 2018/19 academic year. To enter, applicants must submit an online registration form. For further information, email info@vivet.org.uk.
Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.
92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.
According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.
Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.
Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.
Fergus Allerton has become the Editor-in-Chief for Part A: Canine and Feline, whilst Joanna Hedley is the Editor-in-Chief for Part B: Exotic Pets.
For both formularies, the editorial panels have reviewed the drug monographs to make sure all the information is up to date.
Part A includes:
Part B includes:
BSAVA President, Sue Paterson said: "The BSAVA Small Animal Formulary is recognised as an invaluable asset for the small animal clinician and is one of the Association’s most useful member benefits. Busy small animal clinicians in both primary care and referral practice will find this evidence-based resource an invaluable help with immediate prescribing advice."
Eligible BSAVA members will receive a complimentary print copy of Part A: Canine and Feline, and those who renew their membership in 2020 will also receive Part B: Exotic Pets as a loyalty reward gift.
Both Part A and Part B are available:
For more information, visit: https://www.bsava.com.
AniDent is a dental care range for cats and dogs - a rinse, a toothpaste and a gel - created with Virbac to help prevent periodontal disease.
Anident joins VetSoothe, a range of dermatology products which includes shampoos, ear cleaners and skin wipes, developed with Vetruus.
Earlier in the year, IVC also launched Joints & Mobility with Omega-3s, an addition to it's VetPro range, developed with one of the company's orthopaedic experts, Jamie McClement.
On the equine side, the company has also launched EquiXcellence, a range of equine nutritional health and wellbeing supplements.
VetSurgeon asked what longer term plans the company has for its exclusive brand product range.
An IVC Evidensia spokesperson said: "We're developing own brand veterinary products specifically where we think we can see areas we can add value for our practices, pet owners, and patients. In the case of Anident, we saw there was an opportunity to make oral care easier by offering a range of options to suit pet owners' needs.
"In the case of Joints & Mobility with Omega-3s, there is research which has shown that high levels of Omega-3s EPA & DHA can greatly support freedom of movement and pain, which was the key focus when developing the product.
"We plan to continually enhance our own brand portfolio across our UK and Europe practices with some exciting product launches on the horizon."
Photo: Gerhard Putter BVSc MRCVS MANZCVS (Veterinary Dentistry and Oral Surgery) Diplomate of the European Veterinary Dental College uses Anident on a big cat
The improvements include a new cat ward designed to offer a quieter, more relaxing area away from other animals, and a new walk-in dog ward which will allow staff to treat larger breeds of dogs more easily. The intensive care unit has been expanded and the practice has developed a new chemotherapy area.
John Turkington, the partner at Scarsdale Vets responsible for overseeing the work said: "We are already really proud of the state-of-the-art facilities we have at Pride, but we are not complacent and that is why we have made this significant investment to improve our facilities and ultimately the services we offer our clients and patients. Patient comfort is paramount, which is why we’ve invested in an additional walk in ward for our larger breeds, and a new cat ward with a separate feline examination and treatment area."
As well as the changes to improve clinical care, the practice has also invested in its kennelling services, increasing the number of 'suites' for cats and dogs to stay in its 'hotel' areas whilst their owners go on holiday.
John added: "We want Pride to be recognised as one of the best veterinary hospitals in Europe and to make that a reality we have increased our ward capacity for patient comfort and clinical treatment areas, as well as improving facilities behind the scenes for our staff, to create a better working environment. Alongside that the improvements to our Pet Resort will also meet the growing demands from clients for those services."